Research programme: adenosine A2A receptor agonists - Clinical Data

Drug Profile

Research programme: adenosine A2A receptor agonists - Clinical Data

Alternative Names: ATL 1222; ATL908

Latest Information Update: 15 Jul 2015

Price : $50

At a glance

  • Originator Adenosine Therapeutics LLC
  • Developer PGxHealth
  • Class
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 23 Dec 2010 Santen files an IND application with the FDA in the US for Glaucoma and Ocular hypertension
  • 13 Nov 2010 Preclinical trials in Multiple sclerosis in USA (Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top